Articles tagged "Monitoring"

2018 American Transplant Congress
Polyclonal Cellular Immune Function is Dose-Dependently Inhibited by Immunosuppressive Drugs but Has Limited Value in Predicting Infection or Rejection Episodes
S. Marx,¹ C. Adam,² S. Leyking,² U. Sester,² M. Sester.
¹Saarland University, Homburg/Saar, Germany; ²Saarland University, Homburg/Saar, Germany.
Background: Dosage of immunosuppressive drugs in transplant patients must be balanced to prevent graft rejection and infectious complications. Knowledge on general immune function may therefore…
2018 American Transplant Congress
Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in DCD Kidney Transplant Recipients
J. Bank,¹ R. Ruhaak,² D. Soonawala,¹ F. Romijn,² C. van Kooten,¹ C. Cobbaert,² H. de Fijter.¹
¹Nephrology, Leiden University Medical Center, Leiden, Netherlands; ²Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands.
Introduction: Tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) are promising biomarkers in acute kidney injury. Here, we investigated the performance…
2018 American Transplant Congress
Klotho, HMGB-1 and Kynurenine as Marker for Injury and Function in Renal Transplantation
M. Stangl,¹ D. Abendroth.²
¹Transplant Center Munich, Klinikum Großhadern, LMU Munich, Munich, Germany; ²Surgery, University of Ulm, Ulm, Germany.
Brain death is associated with immune activation and tissue injuries, counter regulated by activation of the tryptophan pathway producing kynurenine (Kyn). High mobility group box…
2018 American Transplant Congress
Clinical Validation of a Novel ELISpot-Based In Vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients
B. Banas,¹ D. Steubl,² L. Renders,² D. Chittka,¹ M. Banas,¹ T. Wekerle,³ M. Koch,⁴ O. Witzke,⁵ A. Muehlfeld,⁶ C. Sommerer,⁷ A. Habicht,⁸ C. Hugo,⁹ T. Huenig,¹⁰ M. Lindemann,⁵ T. Schmidt,¹¹ A. Rascle,¹¹ S. Barabas,¹¹ L. Deml,¹¹ R. Wagner,^1,11 B. Kraemer,¹² B. Krueger.¹²
¹University Clinic, Regensburg, Germany; ²Clinic rechts der Isar TUM, Munich, Germany; ³Medical University, Vienna, Austria; ⁴University Clinic, Hamburg-Eppendorf, Germany; ⁵University Hospital, Essen, Germany; ⁶Uniklinik RWTH, Aachen, Germany; ⁷University Hospital, Heidelberg, Germany; ⁸LMU Medical Center, Munich, Germany; ⁹University Hospital, Dresden, Germany; ¹⁰University Hospital, Wuerzburg, Germany; ¹¹Lophius Biosciences, Regensburg, Germany; ¹²UMM Uni. Heidelberg, Mannheim, Germany.
Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause ofCMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually…
2018 American Transplant Congress
Clinically Relevant Variation of Donor-Derived Cell-Free DNA during Longitudinal Surveillance of Renal Allografts
M. Narayanan,¹ T. Alhamad,² D. Hiller,³ J. Yee,³ R. Woodward,³ J. Bromberg.⁴
¹Texas A&M Health Science Center, Temple, TX; ²Washington University School of Medicine, St. Louis, MO; ³CareDx, Brisbane, CA; ⁴University of Maryland School of Medicine, Baltimore, MD.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) levels >1% are associated with active rejection in renal transplant recipients. This report defines the clinically relevant variation of dd-cfDNA…
2018 American Transplant Congress
Estimation of Beta Cell Function after Total Pancreatectomy with Islet Autotransplantation Using Single Fasting Blood Sample Based Indices and Modified Igls Score.
J. Gołębiewska,¹ P. Bachul,² L. Basto,² M. Kijek,² N. Fillman,² K. Cieply,² K. Golab,² L. Wang,² M. Tibudan,² C. Thomas,³ A. Dębska-Ślizień,¹ J. Fung,² P. Witkowski.²
¹Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland; ²Surgery, University of Chicago, Chicago; ³Medicine, University of Chicago, Chicago.
Background: For precise yet logistically feasible evaluation of beta-cell function after total pancreatectomy with islet autotransplantation (TPIAT), we investigated the utility of indices using only…
2018 American Transplant Congress
Four Eyes Are Better Than Two: Improving Laboratory Report Quality Control
S. Dionne,² K. Klama,² H. Rashid,² A. Niedzinski.²
¹Quality Assurance, LABS, Inc., Centennial, CO; ²Infectious Disease, LABS, Inc., Philadelphia, PA.
Background: Our STAT donor-screening lab implemented a new LIMS that is used to manage patient orders, testing and reporting. We intentionally customized the LIMS to…
2018 American Transplant Congress
T Cell Immunomonitoring Including Donor Specific Treg Expansion Prospectively Predicts Renal Allograft Tolerance Induced by Transient Mixed Chimerism
K. Hotta, T. Oura, A. Dehnadi, K. Huh, M. Matsunami, H. Sasaki, G. Benichou, J. Madsen, A. Cosimi, T. Kawai.
Center for Transplant Science, Massachusetts General Hospital, Boston, MA.
Background: Successful induction of allograft tolerance in MHC-mismatched kidney transplantation has been achieved after induction of transient chimerism in both nonhuman primates (NHP) and humans.…
2018 American Transplant Congress
Follow-Up Care of Living Kidney Donors
N. Lam,¹ K. Lentine,² B. Hemmelgarn,³ S. Klarenbach,¹ R. Quinn,³ A. Lloyd,¹ S. Gourishankar,¹ A. Garg.⁴
¹University of Alberta, Edmonton, AB, Canada; ²Saint Louis University, St. Louis, MO; ³University of Calgary, Calgary, AB, Canada; ⁴Western University, London, ON, Canada.
The 2017 KDIGO guidelines recommend that living kidney donors receive lifelong annual follow-up care to assess renal health, including serum creatinine measurements with glomerular filtration…
2018 American Transplant Congress
CMV-Specific Cell-Mediated Immunity after Valgancyclovir Prophylaxis Predicts Late Onset CMV Infection in Kidney Transplant Patients
M. Jarque,¹ E. Crespo,¹ E. Melilli,² A. Manonelles,² N. Montero,² S. Luque,¹ J. Cruzado,^1,2 J. Grinyo,^1,2 O. Bestard.^1,2
¹Experimental Nephrology Laboratory, IDIBELL, Barcelona, Spain; ²Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
Background: There is currently no means to predict late-onset CMV infection after a long course of post-transplant Valgancyclovir prophylaxis therapy and its development still negatively…